win multitud way rais pt
pieri recent present extens preclin clinic data key
opinion leader kol oncolog respiratori diseas highlight scientif
rational behind proprietari product target
local co-stimulatori target partner asthma product receptor
antagonist addit day later announc partnership seattl
genet develop multipl target bispecif immuno-oncolog treatment solid
tumor blood cancer consist belief win
three way proprietari pipelin product partner pipelin product
new partnership deal compani continu valid view incorpor
valuat increas pt previous
stay bullish
rational behind look get stronger multipl
tumor typesgastr bladder breastexpress high level
high unmet need go novel breast gastric etc
tumor progress signific issu approach ad
co-stimulatori target moieti intrigu believ
extens kol present rational go see
exhibit underpin approach use tumor target
keep target local toxic antibodi whittl
clinic develop appetit approach efficaci rational
target still strong believ local co-stimul
ad valuat still conserv estim
probabl achiev sale cancer
frame refer vegf-target antibodi ramucirumab approv
gastric cancer expect sale tumor typewith
potenti clinic uncontrol asthma fascin
us build work done regn/sanofi partner
astrazeneca premier respiratori franchis albeit one need
refresh expect fast-develop biomarker-ori strategi kol
impress potenti inhal therapi vs subq dupi
look forward addit preclin asset come clinic
multipl proprietari partner preclin project
leadership team grown would expect see increas pace
project enter clinic potenti deal like stay bullish
name
biotechnolog compani
technolog creat differenti drug
help patient suffer
cancer sever asthma anemia
medic condit high
analyst certif import disclosur see disclosur appendix
addit partnership compani anticalin compound
pieri offer novel biolog platform base proprietari
anticalin may offer valuabl attribut drug candid
vs target biolog antibodi data
anticalin valid anticalin
platform includ attract valuabl earlier stage
program addit inhal anticalin may open new
opportun target biolog last rang qualiti
partner program provid valid anticalin platform
mad phase studi initi data
phase initi initi safeti pd data
patient expans section phase studi
commenc
addit molecul clinic trial
larg transform partnership anticalin proprietari
new bispecif anticalin move clinic faster anticip
differenti activ immuno-oncolog i/o
anemia ckd competit
partnership disrupt
oncolog i/o clinic trial delay and/or demonstr
pt base sum-of-th part approach valu anemia appli typic
biotech multipl estim ww sale ckd stage patient discount annual assum probabl
market valu approxim bio-dollar potenti mileston royalti could achiev
asthma cancer conserv valu see earli stage pipelin constitut
clinic regulatori commerci intellectu properti manufactur competit strateg financ liquid small-
capit currenc risk
exhibit therapeut impact immunotherapi
exhibit rainbow respons rate
exhibit clinic spectrum sever asthma
exhibit novel treatment landscap sever asthma
exhibit clinic target drug sever asthma
exhibit il-r signal via
exhibit moderate-sever asthma suppress igg mab fab
exhibit highli express human bronchial epithelium
exhibit inhibit vitro
exhibit display potenti risk immunogen
exhibit kinet inhal
exhibit rational uncontrol asthma
incom statement thousand except per revenu expens good gener oper loss incom expens incom tax incom average share outstand average share outstand flow cash gener stock outperform
stock price compani mention report
